glp-1 news today october 20 2025 Perspectives from employers on the costs and issues associated with covering agonists for weight loss GLP-1 RA prescription trends: January

In vitro studies indicate that GLP-1 and its agonist can act directly on pancreatic cells (46, 47)

Currently, tirzepatide is the most promising listed incretin analogue

Body weight loss percentage according to trial Estimated body weight loss percentage, normalised to 24 weeks More Speculative Peptide Drugs It suffices to say that anti-obesity drugs have undergone large gains in outcomes, larger average percentage decreases in weight and reductions in side-effects

Novo Nordisk is awaiting new indications for their injectable semaglutide products

Personalized Wellness Support Relaxing MedSpa Setting Enjoy your B-12 shot in a calm and luxurious environment, designed to make every visit a relaxing experience

And then since he hired me and I had not been there that long, I simply tagged along as the youngest scientist on the team, and then suddenly I became a diabetes researcher